Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5811-5820
DOI: 10.1007/s00259-026-07955-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 30.05.2026. Verfasst von Pierpaolo Alongi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Piazza Marina 61, Palermo, 90139, Italy. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.
Abstract (Originalsprache)
Purpose
To assess the clinical performance of [ 18 F]piflufolastat PET/CT acquired on a total-body 194-cm LAFOV PET/CT system in patients with prostate cancer, with particular focus on detection rate, site-specific disease distribution, and the association between PET findings and serum PSA levels.
Methods
This retrospective single-centre study included 103 consecutive patients with prostate cancer who underwent clinically indicated [ 18 F]piflufolastat PET/CT on 194-cm LAFOV PET/CT. Indications were primary staging ( n = 42) or suspected recurrence ( n = 61). Only the 8-min acquisition dataset was analyzed. PET findings were assessed on a patient basis and across predefined anatomical sites. In the recurrence subgroup, the association between PSA and PET positivity was evaluated using Mann–Whitney U test, logistic regression with log-transformed PSA, ROC analysis, and Spearman correlation with the number of positive sites.
Results
Overall, PET was positive in 91/103 patients (88.3%), negative in 8/103 (7.8%), and indeterminate in 4/103 (3.9%). Positivity was observed in all patients scanned for primary staging (42/42, 100.0%) and in 49/61 patients (80.3%) referred for recurrence. The most frequent positive sites were primary lesion (57.3%), lymph nodes (35.0%), and bone (24.3%). In recurrence, PSA was significantly higher in PET-positive than in non-positive cases (median 2.40 vs. 0.42 ng/mL, p < 0.001). Log-transformed PSA was significantly associated with PET positivity (OR 7.40, 95% CI 2.18–25.11; p = 0.001), with an AUC of 0.912 (95% CI 0.828–0.974). PSA also correlated with the number of positive sites (rho = 0.620, p < 0.001). Conclusion [ 18 F]piflufolastat PET/CT on 194-cm LAFOV PET/CT showed high clinical performance in prostate cancer, with strong PSA-dependent yield in recurrence and effective depiction of site-specific disease distribution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Piazza Marina 61, Palermo, 90139, Italy.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. agostino.chiaravalloti@uniroma2.it.
- IRCCS Neuromed, Via Atinense, 18, Pozzilli, IS, 86077, Italy. agostino.chiaravalloti@uniroma2.it.
- Nuclear Medicine Centre, San Pietro Fatebenefratelli Hospital-Express Diagnostics, Via Cassia 600, Rome, 00189, Italy.
ORCID-Profile: Agostino Chiaravalloti
Förderung
- Università degli Studi di Roma Tor Vergata
Zitieren
APA
Alongi, P., Chiaravalloti, A., Morea, S., & Di Biagio, D. (2026). Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5811-5820. https://doi.org/10.1007/s00259-026-07955-7
Vancouver
Alongi P, Chiaravalloti A, Morea S, Di Biagio D. Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5811-5820. doi:10.1007/s00259-026-07955-7
BibTeX
@article{Alongi2026,
author = {Alongi, Pierpaolo and Chiaravalloti, Agostino and Morea, Simone and Di Biagio, Daniele},
title = {Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {10},
pages = {5811--5820},
doi = {10.1007/s00259-026-07955-7}
}
EUVIMED